modelProcainamide_Grasela1984_reference

Extends from Pharmacolibrary.Pharmacokinetic.Models.PK_1C.

Information

name:procainamide
ATC code:C01BA02
model:one compartment, IV dosing (PK_1C)
source:Grasela TH et al. 1984
population:patients receiving procainamide
measured compound:procainamide
review:accepted with caveats
record page:pharmacolibrary-docs

Parameters as reported in the paper

parametervalueunitmeaning
CLR (L/h)14.4L/hCLR
CLO (L/h)1.2L/hCL
Vd (L)136.0LV
F (Pronestyl®)0.85Pronestyl®Fab
Time to peak (Pronestyl®) [hours]0.70hourstmax
decrease_in_clr_and_cla_associated_with_chf0.11equation variable

About procainamide

Procainamide is a class Ia antiarrhythmic used to treat heart rhythm problems such as atrial fibrillation and supraventricular tachycardia. It is an approved medicine, though it is not authorised in the European Union and is used mainly in other regions.

Summary written by glm-5.3-flash from Wikidata Q417597 and the WHO ATC classification; not checked by a person.

Identity, molar mass and metabolites: Procainamide.

References

  1. Grasela TH et al. (1984). Population pharmacokinetics of procainamide from routine clinical data. Clinical pharmacokinetics 9(6):545–554. DOI:10.2165/00003088-198409060-00004 PUBMED:6509861

Parameters

TypeNameDefaultDescription
RealCl_ref3.333333333333333e-07Cl [m3/s]
RealVd_ref0.136Vd [m3]
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.0009Volume of distribution per kg (default 0.9 L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)1bioavailability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)2.7777777777777776e-7clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1e-4administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Info › Therapeutic range (metadata, not used in equations)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008maximal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Info › Substance metadata
Modelica.Units.SI.MolarMassMM (from PK_1C)0molar mass [kg/mol]; 0 = not supplied (molar concentrations are then 0)
Info › Substance metadata (not used in equations)
Pharmacolibrary.Types.DoseLD50 (from PK_1C)0median lethal dose [mg/kg]; 0 = unknown

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)central-compartment elimination half-life = ln(2)*Vd/Cl (1-compartment approximation; NOT the terminal half-life of 2-/3-compartment models)

Revisions

  • 11/2026 generated by pharmacolibrary-dev export.pharmacolibrary_models from Grasela_1984: parameters extracted from the paper by the pharmacolibrary-dev pipeline, model built by its engineer, reviewed: accepted with caveats